Stock Track | Catalyst Pharmaceuticals Soars 5.10% Pre-Market on Analyst Upgrades and Bullish Outlook

Stock Track11-07

Catalyst Pharmaceuticals (CPRX) stock is surging 5.10% in pre-market trading on Friday, following a series of positive analyst actions that have bolstered investor confidence in the biopharmaceutical company.

The rally comes on the heels of Oppenheimer raising its price target for Catalyst Pharmaceuticals to $33 from $32. Oppenheimer analyst Leland Gershell maintained an Outperform rating on the stock, signaling continued optimism about the company's growth prospects. This upgrade reflects a positive outlook on Catalyst's business model and potential market opportunities.

Adding to the bullish sentiment, Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Catalyst Pharma with an even more optimistic price target of $35.00. This reaffirmation of a strong buy recommendation from a major financial institution has likely contributed to the increased investor enthusiasm, driving the stock's pre-market surge. The convergence of these positive analyst views suggests growing confidence in Catalyst Pharmaceuticals' future performance and market position in the pharmaceutical industry.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1138934251?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 22:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138934251","market":"nz","top_or_hot":-1,"title":"Stock Track | Catalyst Pharmaceuticals Soars 5.10% Pre-Market on Analyst Upgrades and Bullish Outlook","media":"Stock Track","content":"<p>Catalyst Pharmaceuticals (CPRX) stock is surging 5.10% in pre-market trading on Friday, following a series of positive analyst actions that have bolstered investor confidence in the biopharmaceutical company.</p>\n\n<p>The rally comes on the heels of Oppenheimer raising its price target for Catalyst Pharmaceuticals to $33 from $32. Oppenheimer analyst Leland Gershell maintained an Outperform rating on the stock, signaling continued optimism about the company's growth prospects. This upgrade reflects a positive outlook on Catalyst's business model and potential market opportunities.</p>\n\n<p>Adding to the bullish sentiment, Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Catalyst Pharma with an even more optimistic price target of $35.00. This reaffirmation of a strong buy recommendation from a major financial institution has likely contributed to the increased investor enthusiasm, driving the stock's pre-market surge. The convergence of these positive analyst views suggests growing confidence in Catalyst Pharmaceuticals' future performance and market position in the pharmaceutical industry.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Catalyst Pharmaceuticals Soars 5.10% Pre-Market on Analyst Upgrades and Bullish Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Catalyst Pharmaceuticals Soars 5.10% Pre-Market on Analyst Upgrades and Bullish Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-07 22:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Catalyst Pharmaceuticals (CPRX) stock is surging 5.10% in pre-market trading on Friday, following a series of positive analyst actions that have bolstered investor confidence in the biopharmaceutical company.</p>\n\n<p>The rally comes on the heels of Oppenheimer raising its price target for Catalyst Pharmaceuticals to $33 from $32. Oppenheimer analyst Leland Gershell maintained an Outperform rating on the stock, signaling continued optimism about the company's growth prospects. This upgrade reflects a positive outlook on Catalyst's business model and potential market opportunities.</p>\n\n<p>Adding to the bullish sentiment, Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Catalyst Pharma with an even more optimistic price target of $35.00. This reaffirmation of a strong buy recommendation from a major financial institution has likely contributed to the increased investor enthusiasm, driving the stock's pre-market surge. The convergence of these positive analyst views suggests growing confidence in Catalyst Pharmaceuticals' future performance and market position in the pharmaceutical industry.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CPRX","symbol_name":"Catalyst Pharmaceutical Partners","start_time":0,"source_url":"","article_id":"1138934251","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138934251","pubTimestamp":1762526976,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Catalyst Pharmaceuticals (CPRX) stock is surging 5.10% in pre-market trading on Friday, following a series of positive analyst actions that have bolstered investor confidence in the biopharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CPRX":"Catalyst Pharmaceutical Partners"},"translate_title":"个股追踪|Catalyst Pharmaceuticals盘前大涨5.10%，因分析师上调评级和看涨前景","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPRX":1},"content_text":"Catalyst Pharmaceuticals (CPRX) stock is surging 5.10% in pre-market trading on Friday, following a series of positive analyst actions that have bolstered investor confidence in the biopharmaceutical company.\nThe rally comes on the heels of Oppenheimer raising its price target for Catalyst Pharmaceuticals to $33 from $32. Oppenheimer analyst Leland Gershell maintained an Outperform rating on the stock, signaling continued optimism about the company's growth prospects. This upgrade reflects a positive outlook on Catalyst's business model and potential market opportunities.\nAdding to the bullish sentiment, Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Catalyst Pharma with an even more optimistic price target of $35.00. This reaffirmation of a strong buy recommendation from a major financial institution has likely contributed to the increased investor enthusiasm, driving the stock's pre-market surge. The convergence of these positive analyst views suggests growing confidence in Catalyst Pharmaceuticals' future performance and market position in the pharmaceutical industry.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1138934251","isCrawlerRequest":true}